About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2014 (2014), Article ID 108073, 5 pages
Clinical Study

Pelvic Radiation Disease Management by Hyperbaric Oxygen Therapy: Prospective Study of 44 Patients

1Aix-Marseille University, UMR 911, Campus Santé Timone, 13005 Marseille, France
2Department of Digestive Surgery, AP-HM Timone Hospital, Pôle DACCORD, 13385 Marseille, France
3Atelier Provençal d'écriture Médicale, France
4Hyperbaric Medicine, Sainte Marguerite Hospital, Aix-Marseille University, UMR MD2, 13385 Marseille, France
5Department of Gastroenterology, AP-HM Timone Hospital, Pôle DACCORD, 13385 Marseille, France

Received 22 June 2013; Revised 8 October 2013; Accepted 4 November 2013; Published 27 January 2014

Academic Editor: Lorenzo Fuccio

Copyright © 2014 Mehdi Ouaïssi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Pelvic radiation disease (PRD) occurs in 2–11% of patients undergoing pelvic radiation for urologic and gynecologic malignancies. Hyperbaric oxygen therapy (HBOT) has previously been described as a noninvasive therapeutic option for the treatment of PRD. the purpose of study was to analyze prospectively the results of HBOT in 44 consecutive patients with PRD who were resistant to conventional oral or topical treatments. Material and Methods. The median age of the cohort was 65.7 years (39–85). Twenty-seven percent of patients required blood transfusion ( ). The median of delay between radiotherapy and HBOT was 26 months (3–175). We evaluated the results of HBOT, using SOMA-LENT Scale. Results. SOMA-LENT score was decreased in 59% of patient. The median of SOMA-LENT score before HBOT was significantly higher, being equal to 14 (0–36), than after HBOT with the SOMA-LENT score of 12 (0–38) ( ). Tenesmus ( ), bleeding ( ), and ulceration ( ) significantly decreased after HBOT. Regarding patients with colostomy, 33% ( ) benefited from colostomies closure. HBOT was generally well tolerated. Only one patient stopped precociously due to transient myopia. Conclusion. This study is in favor of the interest of HBOT in pelvic radiation disease treatment (PRD).